Bowmed Ibisqus is a market leader in the field of generic injectable antibacterial drugs with a range covering the penicillin, cephalosporin, macrolide and quinolone sub therapy groups. The company was the first to market with generic Piperacillin/Tazobactam in 2008 and continues to expand its portfolio of medicines for the secondary care market. Bowmed Ibisqus also has a strategic interest in developing a sustainable group of niche and innovative hospital products.